Efficacy of two different dosages of prednisone for treatment of subacute thyroiditis: a single-center, prospective, randomized, open-label, non-inferiority trial

Author:

Xu Yiqi1,Zeng Xiaofan1,Liu Shu1,Wu Qian1,Chen Yueping1,He Chunling1,Zhai Qing1,Zhang Binhua1,Gao Jialin1

Affiliation:

1. The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital of Wannan Medical College)

Abstract

Abstract Background: The aim of study was to explore the efficacy and safety of low-dose (LD) and regular dose (RD) prednisone (PDN) for treatment of subacute thyroiditis (SAT). Methods: Patients were randomly allocated using the block randomization method to the two groups. The primary outcome was the time required for PDN treatment. Secondary outcomes included percentages of relapse, mean score for the Morisky Medication Adherence Scale-8©(MMAS-8), time required for symptoms to resolve, cumulative PDN dose (mg) and mean erythrocyte sedimentation rate (ESR) at 2 weeks and baseline. Results: The study cohort included 77 patients, randomized 74 participants, and 68 completed the study. There was no significant difference in the treatment duration between the LD and RD groups (55.31±14.05 vs.61.25±19.95 days, p=0.053). The mean difference in the time required for PDN treatment between the LD and RD groups was -1.86 (95%CI =-10.64 to 6.92) days, which was within the non-inferiority margin of 7 days. There was a significant difference in the mean score for MMAS-8 between the LD and RD groups (5.84±0.88 vs.5.40±1.14, p=0.023). Also, there was a significant difference in the cumulative PDN dose between the LD and RD groups (504.22±236.86 vs.1002.28±309.86, p=0.046). The ESR at 2 weeks was statistically significant as compared to baseline values in both groups, with pre-treatment and post-treatment ESRs of 49.91±24.95 and 17.91±12.60/mm/h, (p<0.0001) in the LD group and 65.08±21.77 and 17.23±13.61/mm/h (p<0.0001) in the RD group. Conclusion: Low-dose PDN therapy may be sufficient to achieve complete recovery and better outcomes of SAT. This study is registered with Chinese Clinical Trial Registry (02/10/2021 ChiCTR2100051762).

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3